Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study
Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study
复制标题
DOI：
10.1158/1055-9965.epi-07-0599
复制
发表时间：
2007-11-01
影响因子：
3.8
通讯作者：
Auvinen, Anssi
中科院分区：
文献类型：
--
作者：
Murtola, Teemu J.;Tammela, Teuvo L. J.;Auvinen, Anssi
背景：先前的研究表明，使用他汀类药物可能会降低前列腺癌的风险。在当前的研究中，我们在人群水平上评估了血清降胆固醇药物的使用与前列腺癌风险的关系。材料和方法：分别从芬兰癌症登记中心和人口登记中心确定了1995-2002年间芬兰所有新诊断的前列腺癌病例和匹配的对照组(24,723例对照)。从芬兰社会保险机构的处方数据库中获取研究期间购买降胆固醇药物的详细信息。结果：在调整了潜在的混杂因素后，曾经使用任何他汀类药物与总体前列腺癌风险略有增加相关[优势比(OR)，1.07；95%可信区间(95%CI)，1.00-1.16]。然而，当单独分析时，没有一种他汀类药物与总体前列腺癌风险相关。另一方面，使用阿托伐他汀、洛伐他汀和辛伐他汀的患者患晚期前列腺癌的风险降低(OR0.61，95%CI 0.37-0.98；OR 0.61，95%CI 0.43-0.85；OR 0.78，95%CI 0.61-1.01)。结论：我们基于人群的大型研究显示，服用降胆固醇药物的人患前列腺癌的总体风险没有下降的证据，而服用他汀类药物的人患晚期癌症的风险降低了。
Background: Previous studies have shown that statin use may reduce prostate cancer risk. In the current study, we evaluated the association between serum cholesterol-lowering medication use and prostate cancer risk at the population level.Materials and Methods: All newly diagnosed prostate cancer cases in Finland during 1995 to 2002 and matched controls (24,723 case control pairs) were identified from the Finnish Cancer Registry and the Population Register Center, respectively. Detailed information on cholesterol-lowering drug purchases during the study period was obtained from the prescription database of the Social Insurance Institution of Finland.Results: After adjustment for potential confounders, having ever-use of any statin was associated with marginally elevated overall prostate cancer risk [odds ratio (OR), 1.07; 95% confidence interval (95% CI), 1.00-1.16]. However, none of the statins was associated with the overall prostate cancer risk when analyzed separately. On the other hand, the risk of advanced prostate cancer was decreased among users of atorvastatin, lovastatin, and simvastatin (OR 0.61, 95% CI 0.37-0.98; OR 0.61, 95% CI 0.43-0.85; and OR 0.78, 95% CI 0.61-1.01, respectively). The risk was not affected among users of other cholesterol drug groups.Conclusions: Our large population-based study showed no evidence for reduced overall prostate cancer risk among users of cholesterol-lowering drugs, whereas the risk of advanced cancer was decreased among statin users.